CureMatch has partnered with WeHealth, the e-health department of Servier Group, to jointly bring the CureMatch digital platform to oncologists, clinics, and hospitals around the world. WeHealth provides CureMatch, a small, innovative company, with the corporate size and infrastructure needed to reach oncologists around the world quickly. Additional valuable benefits of the partnership include the sales and marketing expertise that Servier offers, as well as capabilities to support additional software development and clinical trials.
Servier is an international pharmaceutical company governed by a non-profit foundation and headquartered in Suresnes, France. With a strong international presence in 149 countries and revenue of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, it reinvests 25% of revenue (excluding revenue from generic drug sales) in research and development, and uses all profits to fund further development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory disease, neuropsychiatric diseases, cancer, and diabetes. Servier also manufactures high-quality generic drugs. Servier offers e-health solutions beyond drug development. More information: www.servier.com